Sound View Wealth Advisors Group LLC Acquires 220 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Sound View Wealth Advisors Group LLC lifted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 18.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,420 shares of the company’s stock after acquiring an additional 220 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in Krystal Biotech were worth $222,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in KRYS. Wilmington Savings Fund Society FSB bought a new stake in Krystal Biotech during the 3rd quarter worth approximately $40,000. Huntington National Bank boosted its position in shares of Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after buying an additional 283 shares during the last quarter. KBC Group NV grew its holdings in Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after buying an additional 132 shares in the last quarter. Avanza Fonder AB purchased a new stake in Krystal Biotech in the 4th quarter valued at $119,000. Finally, Blue Trust Inc. lifted its stake in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock valued at $159,000 after acquiring an additional 433 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Citigroup upped their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Jefferies Financial Group started coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Chardan Capital lifted their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech has a consensus rating of “Buy” and a consensus price target of $220.00.

Krystal Biotech Trading Up 2.1 %

Krystal Biotech stock opened at $183.75 on Tuesday. The business’s 50 day simple moving average is $161.66 and its 200 day simple moving average is $174.28. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34. The company has a market cap of $5.29 billion, a price-to-earnings ratio of 61.45 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the prior year, the company earned $0.30 EPS. The firm’s quarterly revenue was up 116.4% compared to the same quarter last year. As a group, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).